Join Us for a Complimentary ACCME- and ANCC-accredited ATTR Breakfast Symposium

Sunday, October 11, 2026 – 7:00 - 8:45 AM MST

Phoenix Ballroom D, Sheraton Phoenix Downtown; Phoenix, AZ

This educational activity is targeted to cardiologists, neurologists, heart failure specialists, and the interprofessional team of nurse practitioners, cardiac nurses, and physician assistants that help manage patients with transthyretin-mediated amyloidosis (ATTR). Designed as a dynamic, interactive, case-driven tour-de-force of the latest data and emerging best practices, this satellite symposium will offer learners an expert-led appraisal of the evolving clinical trial evidence and regulatory updates for novel therapeutics in ATTR, with an emphasis on standard of care treatment selection and sequencing in ATTR-CM, ATTR-PN, and ATTR of mixed phenotype, and will include an intensive review of established and emerging pharmacologic mechanisms and incisively examine how they interface with ATTR pathophysiology. Attendees will also get a unique “glimpse beyond the cutting edge” in a segment led by the two Wiesman Award winners of the 2nd Annual (2025) ATTR Early-Career Research Forum, in which they detail the rationale, design, results, and real-world promise of their original ATTR research projects.

Faculty:

Morie Gertz, MD, FACP (Activity Chair and Moderator)
Rochester, MN

Sami Khella, MD 
Philadelphia, PA

Ahmad Masri, MD, MS
Portland, OR

Jan Griffin, MD
Charleston, SC

American Academy of CME, Inc. will certify this activity for 1.5 hours of ACCME and ANCC credits.